"Journey to the Center of the Earth” has lost none of its fascination to this day. In Jules Verne's fantastic novel, people ...

The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a ...

We are bullish on Avid's potential take-private deal by Ampersand and GHO, predicting value creation and optimistic about ...

BOSTON, Oct. 31, 2024 /PRNewswire/ -- For the third consecutive year, Ampersand Capital Partners has been named to Inc.'s 2024 Founder-Friendly Investors list, which honors the private equity and ...

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector.

Ampersand Biosciences and Trudeau Institute have been awarded more than $1 million to study infectious diseases.